Strategies for reducing treatment default in drug-resistant tuberculosis: Systematic review and meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 299-307

  Toczek, A ^a   Cox, H ^b,c   Du Cros, P ^b   Cooke, G ^a,d   Ford, N ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Default; MDR TB; Retention

Indexed keywords

TUBERCULOSTATIC AGENT;

CONTROL STRATEGY; DRUG RESISTANT TUBERCULOSIS; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SCALE UP; SHORT COURSE THERAPY; SYSTEMATIC REVIEW;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84874042235     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0537     Document Type: Review

References (105)

1. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
3. Gandhi N R, Shah N S, Andrews J R, et al. HIV co-infection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
4. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.
5. Lönnroth K. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375: 1814-1815.
6. Diwan V K. Sex, gender, and tuberculosis. Lancet 1999; 353: 1000-1001.
7. Greene J A. An ethnography of non-adherence: culture, poverty, and tuberculosis in urban Bolivia. Cult Med Psychiatry 2004; 28: 401-425.
8. Munro S A, Lewin S A, Smith H J, Engel M E, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS ONE 2007; 4: 1230-1245.
9. Holtz T H, Lancaster J, Laserson K F, Wells C D, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10: 649-655.
10. Kolappan C, Subramani R, Karunakaran K, Narayanana P R. Mortality of tuberculosis patients in Chennai, India. Bull World Health Organ 2006; 84: 555-560.
11. Verver S, Warren R M, Beyers N, Richardson M, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435.
12. Franke M F, Appleton S C, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008; 46: 1844-1851.
13. Stroup D F, Berlin J A, Morton S C, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
14. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009; 4: e6914.
15. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
16. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
17. Chan E D, Iseman M D. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008; 21: 587-595.
18. Borenstien M, Hedges L, Higgins J P, Rothstein H. Introduction to meta-analysis. Chichester, UK: John Wiley & Sons, 2008: p 312.
19. Newcombe R G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890.
20. World Health Organization. WHO Regional Offices. Geneva, Switzerland: WHO, 2012. http://www.who.int/about/regions/en/index.html Accessed September 2012.
21. The World Bank Group. Country and lending groups. Washington DC, USA: World Bank, 2012. http://data.worldbank.org/about/country-classifications/ country-and-lending-groups Accessed September 2012.
22. World Health Organization. Towards universal access to diagnosis and treatment of multi-drug resistant and extensively drug resistant tuberculosis by 2015. WHO progress report 2011. Geneva, Switzerland: WHO, 2011.
23. Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012; 67: 473-477.
24. Anger H A, Dworkin F, Sharma S, Munsiff S S, Nilsen D M, Ahuja S D. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-783.
25. Banerjee R, Allen J, Westenhouse J, et al. Extensively drugr esistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47: 450-457.
26. Bang D, Lillebaek T, Thomsen V Ø, Andersen Å B. Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992-2007. Scand J Infect Dis 2010; 42: 288-293.
27. Bartu V. Multidrug-resistant tuberculosis in the Czech Republic: strategy and therapeutic outcomes. Eur J Clin Microbiol Infect Dis 2007; 26: 603-605.
28. Bashar M, Alcabes P, Rom W N, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001; 120: 1514-1519.
29. Bendayan D, Hendler A, Polansky V, Weinberger M. Outcome of hospitalized MDR-TB patients: Israel 2000-2005. Eur J Clin Microbiol Infect Dis 2011; 30: 375-379.
30. Bonilla C A, Crossa A, Jave H O, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS ONE 2008; 3: e2957.
31. Bonnet M, Pardini M, Meacci F, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS ONE 2011; 6: e23081.
32. Brust J C, Lyzigos M, Chaiyachati K, et al. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS ONE 2011; 6: e15841.
33. Brust J C M, Gandhi N R, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14: 413-419.
34. Burgos M, Gonzalez L C, Paz E A, et al. Treatment of multi-drug-resistant tuberculosis in San Francisco: an out-patient-based approach. Clin Infect Dis 2005; 40: 968-975.
35. Chiang C, Enarson D A, Yu M, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980-985.
36. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS ONE 2007; 2: e1126.
37. Datta B S, Hassan G, Kadri S M, et al. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2010; 4: 19-23.
38. Dhingra V K, Rajpal S, Mittal A, Hanif M. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc 2008; 55: 15-21.
39. Escudero E, Peña J M, Alvarez-Sala R, Vázquez J J, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis 2006; 10: 409-414.
40. Farley J E, Ram M, Pan W, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS ONE 2011; 6: e20436.
41. Ferrara G, Richeldi L, Bugiani M, et al. Management of multi-drug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9: 507-513.
42. Ferrer G, Acuna-Villaorduna C, Escobedo M, Vlasich E, Rivera M. Outcomes of multidrug-resistant tuberculosis among binational cases in El Paso, Texas. Am J Trop Med Hyg 2010; 83: 1056-1058.
43. Gammino V M, Taylor A B, Rich M L, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011; 15: 1315-1322.
44. Geerligs W A, van Altena R, de Lange W C M, van Soolingen D, van der Werf T S. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
45. Gegia M, Kalandadze I, Kempker R R, Magee M J, Blumberg H M. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2012; 16: 391-396.
46. Gelmanova I Y, Taran D V, Mishustin S P, Golubkov A A, Solovyova A V, Keshavjee S. 'Sputnik': a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. Int J Tuberc Lung Dis 2011; 15: 1373-1379.
47. He G X, Xie Y G, Wang L X, et al. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS ONE 2010; 5: e10799.
48. Heller T, Lessells R L, Wallrauch C G, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010; 14: 420-426.
49. Hersi A, Elwood K, Cowie R, Kunimoto D, Long R. Multidrug-resistant tuberculosis in Alberta and British Columbia. Canada Respir J 1999; 6: 155-160.
50. Isaakidis P, Cox H S, Varghese B, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS ONE 2011; 6: e28066.
51. Jeon D S, Kim D H, Kang H S, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 594-600.
52. Jeon D S, Shin D O, Park S K, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci 2011; 26: 33-41.
53. Joseph P, Desai V B R, Mohan N S, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011; 133: 529-534.
54. Karagoz T, Yazicioglumocin Ö, Pazarli P, et al. The treatment results of patients with multidrug-resistant tuberculosis and factors affecting treatment outcome. Tüberküloz ve toraks 2009; 57: 383-392.
55. Keshavjee S, Gelmanova I G, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
56. Khurram M, Khaar H T B, Fahim M. Multidrug-resistant tuberculosis in Rawalpindi, Pakistan. J Infect Dev Ctries 2012; 6: 29-32.
57. Kim D H, Kim H J, Park S, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-1082.
58. Kim H, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
59. Kim H J, Hong Y P, Kim S J, Lew W J, Lee E G. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
60. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085-1094.
61. Kunawararak P, Pongpanich S, Chantawong S, et al. Tuberculosis treatment with mobile-phone medication reminders in northern Thailand. Southeast Asian J Trop Med Public Health 2011; 42: 1444-1451.
62. Kvasnovsky C L, Cegielski J P, Roshen E, Siwisa N O, Thomas K, van der Walt M L. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIVpositive patients. J Acquir Immune Defic Syndr 2011; 57: 146-152.
63. Kwon Y S, Kim Y H, Suh G Y, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
64. Laniado-Laborín R, Estrada-Guzman J, Perez H, Batiz-Armenta F, Alcantar-Schramm J M. Treatment of multidrug-resistant tuberculosis in a high-prevalence region through a binational consortium. Int J Tuberc Lung Dis 2012; 16: 610-611.
65. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
66. Liu C H, Li L, Chen Z, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS ONE 2011; 6: e19399.
67. Lockman S, Kruuner A, Binkin N J, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis 2001; 32: 373-380.
68. Loveday M, Wallengren K, Voce A, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012; 16: 209-215.
69. Malla P, Kanitz E E, Akhtar M, et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS ONE 2009; 4: e8313.
70. Masjedi M R, Tabarsi P, Baghaei P, et al. Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. Int J Infect Dis 2010; 14: e399-e402.
71. Migliori G B, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
72. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
73. Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
74. Mohammadi A, Nassor Z S, Behlim T, et al. Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman. East Mediterr Health J 2008; 14: 1240-1245.
75. Munsiff S S, Ahuja S D, Li J, Driver C R. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 2006; 10: 639-648.
76. Ollé-Goig J E, Sandy R. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-Plus. Int J Tuberc Lung Dis 2005; 9: 765-770.
77. Palacios E, Franke M, Muñoz M, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis 2012; 16: 348-354.
78. Palmero D J, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-784.
79. Park S K, Lee W C, Lee D H, Mitnick C D, Han L, Seung K J. Self-administered, standardised regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368.
80. Pawar U, Vishal K, Vikas A, Amita N, Nene A. Multidrug-resistant tuberculosis of the spine - is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Spine (Philadelphia) 2009; 34: E806-E810.
81. Rao N A. Treatment outcome of multi-drug resistant tuberculosis in a tertiary care hospital in Karachi. J Pakistan Med A ssoc 2009; 59: 694-698.
82. Riekstina V, Leimane V, Holtz T H, Leimans J, Wells C D. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc Lung Dis 2007; 11: 585-587.
83. Schecter G F, Scott C, True L, Raftery A, Flood J, Mase S. Line-zolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
84. Sharma S K, Kumar S, Saha P K, et al. Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J Med Res 2011; 133: 312-315.
85. Shean K P, Willcox P A, Siwendu S N, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
86. Shin S S, Salmaan Keshavjee S, Gelmanova I Y, et al. Development of extensively drug-resistant tuberculosis during m ultidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182: 426-432.
87. Singla R, Caminero J A, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
88. Singla R, Sarin R, Khalid U K, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009; 13: 976-981.
89. Suárez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
90. Tabarsi P, Chitsaz E, Tabatabaei V, et al. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. Am J Ther 2011; 18: 343-349.
91. Tang S, Zhang Q, Jinming Y, et al. Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes. Scand J Infect Dis 2011; 43: 280-285.
92. Thomas A, Joseph P, Nair D, et al. Extensively drug-resistant tuberculosis: experience at the Tuberculosis Research Centre, Chennai, India. Int J Tuberc Lung Dis 2011; 15: 1323-1325.
93. Törün T, Tahaoǧlu K, Özmen İ, et al. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2007; 11: 979-985.
94. Tupasi T E, Gupta R, Quelapio M I D, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.
95. Van Deun A, Hamid Salim M A, Kumar Das A P, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
96. Vasankari T, Soini H, Liippo K, Ruutu P. MDR-TB in Finland - still rare despite the situation in our neighbouring countries. Clin Respir J 2012; 6: 35-39.
97. Xu H-B, Jiang R-H, Li L, Xiao H-P. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012; 16: 358-363.
98. Jamison D T, Breman J G, Measham A R, et al., eds. Disease control priorities in developing countries. 2nd ed. Washington, DC, USA: World Bank, 2006.
99. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. WHO/HTM/TB/2009. 420. Geneva, Switzerland: WHO, 2009.
100. Mukherjee J S, Eustacheb E. Community health workers as a cornerstone for integrating HIV and primary healthcare. AIDS Care 2007; 19 (Suppl 1): S73-S82.
101. Gler M T, Podewils L J, Munez N, Galipot M, Quelapio M I D, Tupasi T E. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 955-960.
102. London L. Confnement for extensively drug-resistant tuberculosis: balancing protection of health systems, individual rights and the public's health. Int J Tuberc Lung Dis 2009; 13: 1200-1209.
103. Garner P, Smith H, Munro S, Volminkc J. Promoting adherence to tuberculosis treatment. Bull World Health Organ 2007; 85: 404-406.
104. Jain A, Dixit P. Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J Biosci 2008; 33: 605-616.
105. Mills E J, Lester R, Ford N. Adherence to antiretroviral therapy: supervision or support? Lancet Infect Dis 2012; 12: 97-98.